Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aphanizomenon flos-aquae (AFA) extract is a concentrated derivative of a wild-harvested cyanobacterium primarily found in Upper Klamath Lake, Oregon. It is recognized as a nutrient-dense dietary supplement containing high concentrations of phycocyanin, chlorophyll, phenylethylamine (PEA), and essential fatty acids. The extract is most notable in the biotechnology and wellness sectors for its purported ability to support the mobilization of bone marrow-derived stem cells, specifically CD34+ cells, by acting as an L-selectin ligand antagonist. Additionally, it exhibits significant antioxidant and anti-inflammatory properties, largely attributed to phycocyanin, which selectively inhibits cyclooxygenase-2 (COX-2) and reduces oxidative stress. AFA is frequently studied and marketed for its potential benefits in immune system modulation, cognitive enhancement, and mood stabilization due to its unique chemical profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aphanizomenon flos-aquae extract.